Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.

Clinical pharmacology and therapeutics - 1 May 2015

Gerber D E, Oxnard G R, Govindan R

Abstract excerpt

The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Drug Discovery
Share to Early Detection of Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 25677079
DOI: 10.1002/cpt.91
PMCID: PMC4839167

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.PMID 25677079Read ↗

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

The Genomics of Lung Adenocarcinoma: Opportunities for Targeted TherapiesSemantic proximity Read ↗

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.Semantic proximity Read ↗

Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions.Semantic proximity Read ↗

Recent Advances in Personalized Lung Cancer MedicineSemantic proximity Read ↗

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Semantic proximity Read ↗

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.Semantic proximity Read ↗

From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinomaSemantic proximity Read ↗

Recent advances in lung cancer genomics: Application in targeted therapy.Semantic proximity Read ↗

Lung Cancer GenomicsSemantic proximity Read ↗

Lung cancer genotype-based therapy and predictive biomarkers: present and future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.